Symbols / GNPX $1.83 +0.55% Genprex, Inc.

Healthcare • Biotechnology • United States • NCM
GNPX Chart
About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 2.99M
Enterprise Value 3.03M Income -16.77M Sales —
Book/sh 0.77 Cash/sh 0.49 Dividend Yield —
Payout 0.00% Employees 13 IPO —
P/E — Forward P/E -0.84 PEG —
P/S — P/B 2.39 P/C —
EV/EBITDA -0.19 EV/Sales — Quick Ratio 0.43
Current Ratio 0.67 Debt/Eq — LT Debt/Eq —
EPS (ttm) -1261.62 EPS next Y -2.18 EPS Growth —
Revenue Growth — Earnings 2025-05-12 16:00 ROA -273.31%
ROE -14.01% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 1.63M
Shs Float 2.25M Short Float 21.16% Short Ratio 0.42
Short Interest — 52W High 55.00 52W Low 1.71
Beta -0.72 Avg Volume 1.06M Volume 53.97K
Target Price — Recom None Prev Close $1.82
Price $1.83 Change 0.55%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.82
Latest analyst target
3. DCF / Fair value
$-112.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.82
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-05-17 reit HC Wainwright & Co. Buy → Buy $10
2024-05-15 reit HC Wainwright & Co. Buy → Buy $10
2024-04-04 reit HC Wainwright & Co. Buy → Buy $10
2024-04-03 reit HC Wainwright & Co. Buy → Buy $10
2024-03-25 init HC Wainwright & Co. — → Buy $10
News
RSS: Latest GNPX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-22 LONGNECKER BRENT MICHAEL Director — 9,000 $0.00 $0
2025-12-22 BERGER MARK STANLEY Officer — 28,500 $0.00 $0
2025-12-22 CONFER RYAN M. Chief Executive Officer — 45,000 $0.00 $0
2025-12-22 MORENO TOSCANO JOSE ANTONIO Director — 9,000 $0.00 $0
2025-12-22 WILSON WILLIAM R. JR Director — 9,000 $0.00 $0
2024-12-05 LONGNECKER BRENT MICHAEL Director — 4,750 — —
2024-12-05 BERGER MARK STANLEY Officer — 18,250 — —
2024-12-05 CONFER RYAN M. Chief Executive Officer — 29,375 — —
2024-12-05 MORENO TOSCANO JOSE ANTONIO Director — 4,750 — —
2024-12-05 WILSON WILLIAM R. JR Director — 4,750 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
21.17
-31.82%
31.06
+30.32%
23.83
+15.29%
20.67
Research And Development
10.54
-40.20%
17.62
+53.05%
11.51
+28.31%
8.97
Selling General And Administration
10.63
-20.81%
13.43
+9.19%
12.30
+5.30%
11.68
General And Administrative Expense
10.63
-20.81%
13.43
+9.19%
12.30
+5.30%
11.68
Other Gand A
10.63
-20.81%
13.43
+9.19%
12.30
+5.30%
11.68
Total Expenses
21.17
-31.82%
31.06
+30.32%
23.83
+15.29%
20.67
Operating Income
-21.17
+31.82%
-31.06
-30.32%
-23.83
-15.29%
-20.67
Total Operating Income As Reported
-21.17
+31.82%
-31.06
-30.32%
-23.83
-15.29%
-20.67
EBITDA
-21.17
+31.81%
-31.04
-30.40%
-23.81
-15.29%
-20.65
Normalized EBITDA
-21.17
+31.81%
-31.04
-30.40%
-23.81
-15.29%
-20.65
Reconciled Depreciation
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
EBIT
-21.17
+31.82%
-31.06
-30.32%
-23.83
-15.29%
-20.67
Net Income
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Pretax Income
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Net Non Operating Interest Income Expense
0.06
-70.45%
0.22
+138.75%
0.09
+1655.27%
0.01
Net Interest Income
0.06
-70.45%
0.22
+138.75%
0.09
+1655.27%
0.01
Interest Income Non Operating
0.06
-70.45%
0.22
+138.75%
0.09
+1655.27%
0.01
Interest Income
0.06
-70.45%
0.22
+138.75%
0.09
+1655.27%
0.01
Other Income Expense
-0.00
+96.95%
-0.02
—
—
Other Non Operating Income Expenses
-0.00
+96.95%
-0.02
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Net Income From Continuing Operation Net Minority Interest
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Net Income From Continuing And Discontinued Operation
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Net Income Continuous Operations
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Normalized Income
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Net Income Common Stockholders
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Diluted EPS
-5.34
+76.33%
-22.56
+97.72%
-990.00
-12.50%
-880.00
Basic EPS
-5.34
+76.33%
-22.56
+97.72%
-990.00
-12.50%
-880.00
Basic Average Shares
4.01
+192.89%
1.37
+14.09%
1.20
+1.82%
1.18
Diluted Average Shares
4.01
+192.89%
1.37
+14.09%
1.20
+1.82%
1.18
Diluted NI Availto Com Stockholders
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Depreciation Amortization Depletion Income Statement
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
Depreciation And Amortization In Income Statement
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
Depreciation Income Statement
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
4.12
-61.35%
10.67
-57.46%
25.09
-41.48%
42.86
Current Assets
2.08
-72.42%
7.53
-64.92%
21.47
-45.14%
39.14
Cash Cash Equivalents And Short Term Investments
1.60
-76.23%
6.74
-67.85%
20.95
-45.76%
38.63
Cash And Cash Equivalents
1.60
-76.23%
6.74
-67.85%
20.95
-45.76%
38.63
Cash Financial
1.60
—
20.95
-45.76%
38.63
Receivables
—
0.00
-100.00%
0.03
0.00
Accounts Receivable
—
0.00
-100.00%
0.03
0.00
Prepaid Assets
—
—
—
0.51
Other Current Assets
0.48
-40.09%
0.79
+64.00%
0.48
-5.30%
0.51
Total Non Current Assets
2.05
-34.79%
3.14
-13.10%
3.61
-2.96%
3.72
Net PPE
0.00
-100.00%
0.01
-65.88%
0.02
-52.62%
0.05
Goodwill And Other Intangible Assets
0.00
-100.00%
0.77
+10.17%
0.70
+9.30%
0.64
Other Intangible Assets
—
0.77
+10.17%
0.70
+9.30%
0.64
Non Current Prepaid Assets
0.00
-100.00%
0.01
-54.17%
0.02
+151.04%
0.01
Other Non Current Assets
2.05
-12.81%
2.35
-18.06%
2.86
-5.21%
3.02
Total Liabilities Net Minority Interest
2.50
-23.05%
3.25
+15.80%
2.81
+77.27%
1.59
Current Liabilities
2.50
-23.05%
3.25
+15.80%
2.81
+77.27%
1.59
Payables And Accrued Expenses
1.07
-23.13%
1.40
+215.54%
0.44
-54.49%
0.97
Payables
1.07
-23.13%
1.40
+215.54%
0.44
-54.49%
0.97
Accounts Payable
1.07
-23.13%
1.40
+215.54%
0.44
-54.49%
0.97
Other Current Liabilities
1.43
-22.98%
1.86
-21.58%
2.37
+286.76%
0.61
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
1.62
-78.15%
7.42
-66.70%
22.27
-46.04%
41.28
Common Stock Equity
1.62
-78.15%
7.42
-66.70%
22.27
-46.04%
41.28
Capital Stock
0.01
+630.89%
0.00
+23.52%
0.00
-97.49%
0.05
Common Stock
0.01
+630.89%
0.00
+23.52%
0.00
-97.49%
0.05
Preferred Stock
0.00
0.00
—
—
Share Issued
10.86
+630.91%
1.49
+23.55%
1.20
+0.48%
1.20
Ordinary Shares Number
10.86
+630.91%
1.49
+23.55%
1.20
+0.48%
1.20
Additional Paid In Capital
156.41
+10.85%
141.10
+12.79%
125.10
+3.98%
120.32
Retained Earnings
-154.80
-15.79%
-133.69
-30.01%
-102.83
-30.02%
-79.09
Total Equity Gross Minority Interest
1.62
-78.15%
7.42
-66.70%
22.27
-46.04%
41.28
Total Capitalization
1.62
-78.15%
7.42
-66.70%
22.27
-46.04%
41.28
Working Capital
-0.43
-109.98%
4.28
-77.08%
18.66
-50.31%
37.55
Invested Capital
1.62
-78.15%
7.42
-66.70%
22.27
-46.04%
41.28
Net Tangible Assets
1.62
-75.61%
6.64
-69.21%
21.57
-46.91%
40.63
Tangible Book Value
1.62
-75.61%
6.64
-69.21%
21.57
-46.91%
40.63
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-17.15
+30.68%
-24.74
-40.39%
-17.62
-23.36%
-14.28
Cash Flow From Continuing Operating Activities
-17.15
+30.68%
-24.74
-40.39%
-17.62
-23.36%
-14.28
Net Income From Continuing Operations
-21.11
+31.59%
-30.86
-29.99%
-23.74
-14.88%
-20.66
Depreciation Amortization Depletion
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
Depreciation
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
Depreciation And Amortization
0.01
-55.39%
0.02
-41.33%
0.03
+13.50%
0.02
Other Non Cash Items
0.77
—
-0.00
—
Stock Based Compensation
3.30
-38.93%
5.41
+14.30%
4.73
-11.51%
5.35
Change In Working Capital
-0.12
-117.34%
0.70
-48.73%
1.36
+34.82%
1.01
Change In Receivables
0.00
-100.00%
0.03
+200.00%
-0.03
-27542.52%
0.00
Changes In Account Receivables
0.00
-100.00%
0.03
+200.00%
-0.03
-27542.52%
0.00
Change In Prepaid Assets
0.33
+210.14%
-0.30
-2229.56%
0.01
+111.22%
-0.12
Change In Payables And Accrued Expense
-0.32
-133.87%
0.95
+280.04%
-0.53
-167.96%
0.78
Change In Payable
-0.32
-133.87%
0.95
+280.04%
-0.53
-167.96%
0.78
Change In Account Payable
-0.32
-133.87%
0.95
+280.04%
-0.53
-167.96%
0.78
Change In Other Working Capital
—
0.52
+228.61%
0.16
—
Change In Other Current Assets
0.30
-41.90%
0.52
+228.61%
0.16
—
Change In Other Current Liabilities
-0.43
+16.45%
-0.51
-129.10%
1.76
+395.36%
0.35
Investing Cash Flow
0.00
+101.64%
-0.07
-19.22%
-0.06
+28.71%
-0.08
Cash Flow From Continuing Investing Activities
0.00
+101.64%
-0.07
-19.22%
-0.06
+28.71%
-0.08
Net PPE Purchase And Sale
0.00
+589.94%
0.00
0.00
+100.00%
-0.03
Purchase Of PPE
—
—
0.00
+100.00%
-0.03
Sale Of PPE
0.00
+589.94%
0.00
0.00
—
Capital Expenditure
—
-0.07
-19.50%
-0.06
+28.71%
-0.08
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.07
-19.50%
-0.06
-14.66%
-0.05
Purchase Of Intangibles
0.00
+100.00%
-0.07
-19.50%
-0.06
-14.66%
-0.05
Net Other Investing Changes
—
—
0.00
+163.16%
0.00
Financing Cash Flow
12.01
+13.39%
10.59
+164751.81%
0.01
-99.97%
25.68
Cash Flow From Continuing Financing Activities
12.01
+13.39%
10.59
+164751.81%
0.01
-99.97%
25.68
Net Common Stock Issuance
12.01
+13.39%
10.59
+164751.81%
0.01
-99.97%
25.68
Changes In Cash
-5.14
+63.87%
-14.22
+19.57%
-17.67
-256.29%
11.31
Beginning Cash Position
6.74
-67.85%
20.95
-45.76%
38.63
+41.40%
27.32
End Cash Position
1.60
-76.23%
6.74
-67.85%
20.95
-45.76%
38.63
Free Cash Flow
-17.15
+30.88%
-24.81
-40.32%
-17.68
-23.05%
-14.37
Common Stock Issuance
12.01
+13.39%
10.59
+164751.81%
0.01
-99.97%
25.68
Issuance Of Capital Stock
12.01
+13.39%
10.59
+164751.81%
0.01
-99.97%
25.68
Sale Of Intangibles
—
—
0.16
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category